All In Biotech

Drug Trial Radar · NCT05846230

Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine

A Randomised, Double-blind, Parallel Group, Roll-over Study Evaluating Long-term Safety and Efficacy of Oral Doses of BI 1291583 q.d. in Patients With Bronchiectasis (Clairleafᵀᴹ)

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 268 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

268

Actual

Start

Sep 8, 2023

Primary completion

Mar 31, 2027

Study completion Mar 31, 2027

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
May 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults aged 18 years and older with bronchiectasis. People can join the study if they were previously enrolled in another study with BI 1291583 (1397-0012: Airleafᵀᴹ or 1397-0013 Clairaflyᵀᴹ). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis, an inflammatory lung condition. The investigators also want to know how well people with this condition can tolerate BI 1291583 in the long term. Participants take a low, medium, or high dose of BI 1291583 as a tablet once a day for up to 1 year. Participants who were taking placebo in the AirleafTM or ClairaflyTM study are put into the BI 1291583 dosage groups randomly, which means by chance. Placebo tablets look like BI1291583 but do not contain any medicine. Participants who were taking BI 1291583 in the AirleafTM or ClairaflyTM study continue to take the same dose. Participants visit the study site 10 times and get 4 phone calls from the site staff. During the visits, the doctors collect information on any health problems of the participants. The doctors also check whether BI 1291583 helps reduce the symptoms of bronchiectasis.

Conditions

  • Bronchiectasis

Interventions

  • BI 1291583Drug

    Tablet

  • Placebo matching BI 1291583Drug

    Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of treatment-emergent adverse events (TEAEs)Time frame: up to 12 months

Locations

103 sites in 22 countries. Site status is shown where the registry gives one.

  • Newport Native MD, Inc

    Newport Beach, California

  • University of California Davis

    Sacramento, California

  • Malcom Randall VA Medical Center

    Gainesville, Florida

  • University of Florida Health Jacksonville

    Jacksonville, Florida

  • University of Kansas Medical Center

    Kansas City, Kansas

  • New York University Langone Medical Center

    New York, New York

  • University of Cincinnati

    Cincinnati, Ohio

  • Medical University of South Carolina

    Charleston, South Carolina

  • Metroplex Pulmonary & Sleep Center

    McKinney, Texas

  • IMA Clinical Research San Antonio

    San Antonio, Texas

  • University of Texas Health Science Center at Tyler

    Tyler, Texas

  • Macquarie University

    Macquarie Park, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Lung Research Queensland

    Chermside, Queensland, Australia

  • Mater Research Institute

    South Brisbane, Queensland, Australia

  • Institute for Respiratory Health

    Nedlands, Western Australia, Australia

  • Trialswest

    Spearwood, Western Australia, Australia

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Medical Center Zdrave-1 OOD

    Kozloduy, Bulgaria

  • Medical Center Hera - Montana Branch

    Montana, Bulgaria

  • Medical Center ReSpiro Ltd

    Razgrad, Bulgaria

  • Specialized Hospital For Active Treatment Of Pneumo-Phthisiatric Diseases Dr. Dimitar Gramatikov-Ruse

    Rousse, Bulgaria

  • Medical Center Hera EOOD

    Sofia, Bulgaria

  • Institut Universitaire de Cardiologie et de Pneumologie de Quebec (IUCPQ)

    Québec, Canada

  • Centre Hospitalier de l'Universite de Montreal (CHUM)

    Montreal, Quebec, Canada

  • Pulmonary Private Practice Kralupy

    Kralupy nad Vltavou, Czechia

  • The First Pulmonary Private Practice

    Prague, Czechia

  • Aalborg Sygehus Syd

    Aalborg, Denmark

  • Hvidovre Hospital

    Hvidovre, Denmark

  • Copenhagen University Hospital, Rigshospitalet

    København Ø, Denmark

  • Odense University Hospital

    Odense, Denmark

  • Sjællands Universitetshospital

    Roskilde, Denmark

  • Vejle University Hospital

    Vejle, Denmark

  • CHU Amiens-Picardie

    Amiens, France

  • HOP Arnaud de Villeneuve

    Montpellier, France

  • HOP Pontchaillou

    Rennes, France

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany

  • Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH

    Essen, Germany

  • IKF Pneumologie GmbH & Co. KG

    Frankfurt, Germany

Showing 40 of 103 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.